ID - 1053
QUANTUM-WILD: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF QUIZARTINIB IN COMBINATION WITH CHEMOTHERAPY AND AS SINGLE-AGENT MAINTENANCE IN FLT3-ITD–NEGATIVE ACUTE MYELOID LEUKEMIA
P MontesinosaD Azzi-NogueirabJ CheongcN DaverdAT FathieMJ LevisfS LugergT MiyamotohEN OlivaiAE PerlgC RécherjL BullingerkJ WanglAM ZeidanmL LiunY DuongnK ImadalounK AlexisnA NaharnK BurnsnHP Erbao
a Hematology, Hospital Universitari I Politécnic La Fe and Programa Español de Tratamientos en Hematología (PETHEMA) Group, Valencia, Spain
b Daiichi Sankyo Brasil Farmacêutica Ltda., São Paulo, Brazil
c Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea
d Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, United States
e Massachusetts General Hospital Cancer Center, Boston, United States
f Johns Hopkins University, Baltimore, United States
g University of Pennsylvania, Philadelphia, United States
h Department of Hematology, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
i Hematology Department, London North West University Healthcare NHS Trust, London, United Kingdom
j Service d'hématologie, Centre Hospitalo-universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, UPS, Service d'hématologie, Toulouse, France
k Department of Hematology, Oncology and Cancer Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany
l State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Disease, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
m Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, United States
n Daiichi Sankyo, Inc., Basking Ridge, United States
o Duke Cancer Institute, Durham, United States
Ver más
